natgillin/translations-raw huggingface dataset:
25% opløseligt insulin og 75% krystallinsk protamininsulin • Insuman Comb 50:
25% soluble insulin and 75% crystalline protamine insulin; • Insuman Comb 50:
Insuman anvendes til patienter med sukkersyge, der har behov for behandling med insulin.
Insuman is used in patients with diabetes who need treatment with insulin.
Insuman Rapid kan desuden anvendes til behandling af hyperglykæmisk koma (bevidstløshed forårsaget af for høj blodglukose (blodsukker)) og ketoacidose (høje koncentrationer af ketoner [syrer] i blodet), samt til regulering af blodglukosen før, under og efter en operation.
Insuman Rapid can also be used for the treatment of hyperglycaemic coma (coma caused by too much blood glucose [sugar]) and ketoacidosis (high levels of ketones [acids] in the blood), and to control blood glucose before, during or after an operation.
Insuman indgives ved injektion under huden, sædvanligvis i bugvæggen (maveskindet) eller i låret, som anbefalet af lægen.
Insuman is given by injection under the skin, generally in the abdominal wall (tummy) or the thigh, according to the doctor’ s recommendations.
Det ønskede blodglukoseniveau, hvilken type Insuman der skal anvendes, samt dosis og tidspunktet for injektionerne besluttes af lægen for den enkelte patient og tilpasses patientens diæt, fysiske aktivitet og livsstil.
The desired blood glucose levels, type of Insuman to be used, and the dose and timing of injections are determined by the doctor for each patient individually, and are adjusted to suit the patient ’ s diet, physical activity and lifestyle.
Patientens blodglukose skal kontrolleres regelmæssigt, så man kan finde den laveste dosis, der er effektiv.
The patient ’ s blood glucose should be tested regularly to find the lowest effective dose.
Insuman skal indgives før et måltid (nøjagtige tidsangivelser findes i indlægssedlen).
See the Package Leaflet for exact timings.
Insuman Rapid kan desuden indgives i en vene, men kun i hospitalsomgivelser, hvor patienten kan overvåges nøje.
Insuman Rapid may also be given into a vein, but only in hospital where the patient can be closely monitored.
Insuman Infusat er specielt fremstillet til anvendelse i infusionspumper.
Insuman Infusat is specially prepared ready to be used in infusion pumps.
Sukkersyge er en sygdom, hvor kroppen ikke producerer tilstrækkeligt med insulin til at regulere blodglukoseniveauet.
Diabetes is a disease in which the body does not produce enough insulin to control the level of blood glucose.
Insuman er et erstatningsinsulin, som er identisk med det, der produceres af kroppen.
Insuman is a replacement insulin that is identical to the insulin made by the body.
Det aktive stof i Insuman, insulin human, fremstilles ved en metode, der kaldes "rekombinant dna - teknologi": det produceres af en bakterie, der har fået indsat et gen (dna), som gør den i stand til at producere insulin.
The active substance in Insuman, insulin human, is produced by a method known as ‘ recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce insulin.
Insuman indeholder forskellige former for insulin: den opløselige form, der er hurtigtvirkende (inden for 30 minutter efter injektion), og isophan - og krystallinske protaminformer, der optages meget langsommere dagen igennem, hvorved de virker længere.
Insuman contains insulin in various forms: the soluble form, which acts quickly (within 30 minutes of injection), and the isophane and crystalline-protamine forms, which are absorbed much more slowly during the day, giving them a longer duration of action.
Erstatningsinsulinet virker på samme måde som naturligt produceret insulin og bevirker, at sukkeret fra blodet føres ind i cellerne.
The replacement insulin acts in the same way as naturally produced insulin and helps glucose enter cells from the blood.
Gennem regulering af blodglukosen mindskes symptomerne og komplikationerne ved sukkersygen.
By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced.
Insuman er blevet undersøgt i to undersøgelser med 611 patienter, enten med type 1 sukkersyge (hvor bugspytkirtlen ikke kan producere insulin) eller med type 2 sukkersyge (hvor kroppen ikke kan udnytte insulinet effektivt).
Insuman has been studied in two trials in 611 patients with either type 1 diabetes (when the pancreas cannot produce insulin) or type 2 diabetes (when the body is unable to use insulin effectively).
I den ene af undersøgelserne blev Insuman anvendt i en insulinpumpe.
In one of the studies, Insuman was used in an insulin pump.
I den anden undersøgelser blev Insuman Comb 25 sammenlignet med halvsyntetisk humant insulin.
In the other study, Insuman Comb 25 was compared with semi-synthetic human insulin.
I undersøgelserne måltes det ” fastende ” blodglukoseniveau eller koncentrationen af et stof i blodet kaldet glykosyleret hæmoglobin (HbA1c), der giver et fingerpeg om, hvor velreguleret blodglukosen er.
The studies measured the ‘ fasting’ blood glucose levels (measured when the patient had not eaten for at least eight hours) or a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
Insuman bevirkede et fald i indholdet af HbA1c som tegn på, at blodglukoseniveauet var blevet reguleret til et niveau svarende til det, der opnås med halvsyntetisk humant insulin.
Insuman led to a decrease in the level of HbA1c, indicating that blood glucose levels had been controlled to a similar level to that seen with semi-synthetic human insulin.
Insuman var effektivt både til type 1 og type 2 sukkersyge.
Insuman was effective for both type 1 and type 2 diabetes.
Insuman kan medføre hypoglykæmi.
Insuman may cause hypoglycaemia.
Den fuldstændige liste over de indberettede bivirkninger ved Insuman fremgår af indlægssedlen.
For the full list of all side effects reported with Insuman, see the Package Leaflet.
Insuman må ikke anvendes hos patienter, der kan være overfølsomme (allergiske) over for insulin human eller andre af indholdsstofferne.
Insuman should not be used in people who may be hypersensitive (allergic) to insulin human or any of the other ingredients.
Det kan desuden være nødvendigt at justere doseringen af Insuman, når det gives sammen med andre lægemidler, der kan påvirke blodglukoseniveauet.
Insuman doses might also need to be adjusted when it is given with other medicines that may have an effect on blood glucose levels.
Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Insuman er større end risiciene til behandling af sukkersyge (diabetes mellitus).
The Committee for Medicinal Products for Human Use (CHMP) decided that Insuman’ s benefits are greater than its risks for the treatment of diabetes mellitus.
Andre oplysninger om Insuman:
Other information about Insuman:
Europa- Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Insuman til Sanofi Aventis Deutschland GmbH den 21. februar 1997.
The European Commission granted a marketing authorisation valid throughout the European Union for Insuman to Sanofi-Aventis Deutschland GmbH on 21 February 1997.
Markedsføringstilladelsen blev fornyet den 21. februar 2002 og den 21. februar 2007.
The marketing authorisation was renewed on 21 February 2002 and on 21 February 2007.
Den fuldstændige EPAR for Insuman findes her.
The full EPAR for Insuman is available here.
Dette sammendrag blev sidst ajourført i 11- 2008
This summary was last updated in 11-2008
EU- nummer EU/ 1/ 97/ 030/ 028
EU/ 1/ 97/ 030/ 028
Særnavn Insuman Rapid
Insuman Rapid
Indgivelsesvej Subkutan, intramuskulær eller intravenøs anvendelse
Subcutaneous or intravenous use
Indhold 5 ml
5 ml
Subkutan, intramuskulær eller intravenøs anvendelse
Subcutaneous or intravenous use
Hætteglas (glas)
vials (glass)
5 cylinderampul - ler
5 cartridges
Subkutan, intramusulær eller intravenøs anvendelse
Subcutaneous or intravenous use
Subkutan eller intramuskulær anvendelse
Subcutaneous use
1/ 12 EU- nummer EU/ 1/ 97/ 030/ 041
EU/ 1/ 97/ 030/ 041
Særnavn Insuman Comb 15
Insuman Comb 15
Indgivelsesvej Subkutan eller intramuskulær anvendelse
Subcutaneous use
Hætteglas (glas))
vial (glass)
Lægemiddelform Injektionsvæske, opløsning
Solution for injection Solution for injection Solution for injection
Subkutan eller intramuskulær anvendelse
Subcutaneous use Subcutaneous use Subcutaneous or intravenous use
Cylinderampul (glas)
vial (glass) cartridge (glass) cartridge (glass)
4 cylinderampul - ler
3 vials 5 cartridges 4 cartridges
Subkutan eller intramuskulær anvendelse
Subcutaneous or intravenous use
10 cylinderampul - ler
10 cartridges
4 cylinderampul - ler
4 cartridges
OptiSet, Injektionsvæske, opløsning
OptiSet, solution for injection
Cylinderampul (glas) i engangspen
cartridge (glass) in disposable pen
3/ 12 EU- nummer EU/ 1/ 97/ 030/ 067
EU/ 1/ 97/ 030/ 067
Lægemiddelform OptiSet, Injektionsvæske, opløsning
OptiSet, solution for injection
Emballage Cylinderampul (glas) i engangspen
cartridge (glass) in disposable pen
Pakningsstørrelse 5 penne
5 pens
OptiSet, Injektionsvæske, suspension
OptiSet, suspension for injection
Cylinderampul (glas) i engangspen
cartridge (glass) in disposable pens
4/ 12 EU- nummer EU/ 1/ 97/ 030/ 080
EU/ 1/ 97/ 030/ 080
Særnavn Insuman Comb 25
Insuman Comb 25
Lægemiddelform OptiSet, Injektionsvæske, suspension
OptiSet, suspension for injection
Emballage Cylinderampul (glas) i engangspen
cartridge (glass) in disposable pens
5/ 12 EU- nummer EU/ 1/ 97/ 030/ 097
EU/ 1/ 97/ 030/ 097
Emballage Cylinderampul (glas)
cartridge (glass)
Pakningsstørrelse 9 cylinderampuller
9 cartridges
6/ 12 EU- nummer EU/ 1/ 97/ 030/ 111
EU/ 1/ 97/ 030/ 111
7/ 12 EU- nummer EU/ 1/ 97/ 030/ 124
EU/ 1/ 97/ 030/ 124
8/ 12 EU- nummer EU/ 1/ 97/ 030/ 137
EU/ 1/ 97/ 030/ 137
Særnavn Insuman Comb 50
Insuman Comb 50
Cylinderampul (glas) i engangspen (SoloStar)
cartridge (glass) in pre- filled pen (SoloStar)
3 Penne
3 pre-filled pens
4 Penne
4 pre-filled pens
5 Penne
5 pre-filled pens
6 Penne
6 pre-filled pens
9 Penne
9 pre-filled pens
10 Penne
10 pre-filled pens
9/ 12 EU- nummer EU/ 1/ 97/ 030/ 147
EU/ 1/ 97/ 030/ 147
Særnavn Insuman Basal
Insuman Basal
Emballage Cylinderampul (glas) i engangspen (SoloStar)
cartridge (glass) in pre- filled pen (SoloStar)
Pakningsstørrelse 4 Penne
4 pre-filled pens
10/ 12 EU- nummer EU/ 1/ 97/ 030/ 157
EU/ 1/ 97/ 030/ 157
Pakningsstørrelse 10 Penne
10 pre-filled pens
11/ 12 EU- nummer EU/ 1/ 97/ 030/ 167
EU/ 1/ 97/ 030/ 167
Pakningsstørrelse 6 Penne
6 pre-filled pens
12/ 12
9/ 9
PRODUKTRESUME
SUMMARYOF PRODUCT CHARACTERISTICS
Insuman Rapid 100 IE/ ml injektionsvæske, opløsning, i hætteglas
Insuman Rapid 100 IU/ ml solution for injection in a vial
Hver ml indeholder 100 IE human insulin (svarende til 3, 5 mg). Hvert hætteglas indeholder 5 ml injektionsvæske, opløsning svarende til 500 IE insulin.
Each vial contains 5 ml of solution for injection, equivalent to 500 IU insulin.
Insuman Rapid er en neutral insulinopløsning (regular insulin)
Insuman Rapid is a neutral insulin solution (regular insulin).
Insuman Rapid kan også anvendes til behandling af hyperglykæmisk coma og ketoacidose samt til præ -, per - og post- operativ stabilisering af patienter med diabetes mellitus.
Insuman Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and post-operative stabilisation in patients with diabetes mellitus.
Det ønskede blodglukoseniveau, det anvendte insulin- præparat og insulin- doseringen (dosis og tidspunkt) fastlægges individuelt, og skal tilpasses patientens kostvaner, fysiske aktivitet og levevis.
The desired blood glucose levels, the insulin preparations to be used and the insulin dosage (doses and timings) must be determined individually and adjusted to suit the patient’ s diet, physical activity and life- style.
Omstilling til Insuman Rapid
2 Transfer to Insuman Rapid
- andre omstændigheder opstår, som øger følsomheden over for hypoglykæmi eller hyperglykæmi
- other circumstances arise that may promote an increased susceptibility to hypo- or hyperglycaemia
Insuman Rapid indeholder 100 IE insulin pr. ml opløsning.
Insuman Rapid contains 100 IU of insulin per ml solution.
Insuman Rapid må ikke anvendes i eksterne eller implanterede insulinpumper eller i peristaltiske pumper med silikoneslanger.
Insuman Rapid must not be used in external or implanted insulin pumps or in peristaltic pumps with silicone tubing.
Patienter, der er overfølsomme over for Insuman Rapid, men hvor et bedre behandlingsalternativ ikke findes, må kun fortsætte behandlingen under særlig nøje kontrol og - om nødvendigt - i forbindelse med samtidig anti- allergisk behandling.
Patients hypersensitive to Insuman Rapid for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti- allergic treatment.
3 Inden omstilling til Insuman Rapid anbefales det at foretage en intradermal hudtest på de patienter, der er allergiske over for animalsk insulin, da disse patienter kan udvikle immunologiske krydsreaktioner.
In patients with an allergy to animal insulin intradermal skin testing is recommended prior to a transfer to Insuman Rapid, since they may experience immunological cross-reactions.
- visse ukompenserede endokrine lidelser (fx hypothyroidisme, hypofyseforlap eller
- certain uncompensated endocrine disorders (e. g. in hypothyroidism and in anterior pituitary or
Amning
5 Lactation
Insuman Rapid kan anvendes under amning.
Insuman Rapid can be used during breastfeeding.
Hos mange patienter ses tegn på adrenerg modregulation forud for tegn og symptomer på neuroglykopeni.
In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter- regulation.
I sjældne tilfælde kræver forekomsten af sådanne insulinantistoffer justering af insulindosis for at korrigere for tendensen til udvikling af hyper - eller hypoglykæmi.
In rare cases, the presence of such anti- insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.
Øjensygdomme
6 Eyes disorders
- øger glukosetransporten ind i cellerne, fremmer glykogendannelsen i muskler og lever, og
- increases the transport of glucose into cells as well as the formation of glycogen in the muscles and
forbedrer udnyttelsen af pyruvat.
the liver, and improves pyruvate utilisation.
Produktet kan anvendes i op till 4 uger og ikke over 25°C, væk fra direkte varme eller direkte lys.
The product may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
6. 4 Særlige opbevaringsforhold
8 6.4 Special precautions for storage
Insuman Rapid må kun anvendes, såfremt opløsningen er klar, farveløs, uden synlige partikler og har et vandlignende udseende.
Insuman Rapid must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of a water-like consistency.
Insuman Rapid må i lighed med andre insulinpræparater ikke blandes med opløsninger, der indeholder reducerende stoffer som thioler og sulfitter.
As with all insulin preparations, Insuman Rapid must not be mixed with solutions containing reducing agents such as thioles and sulphites.
Insuman Rapid kan blandes med alle humane insuliner fra Sanofi- Aventis, men IKKE med dem der er designet til anvendelse i insulinpumper.
Insuman Rapid may be mixed with all Sanofi-Aventis human insulins, but NOT with those designed specifically for use in insulin pumps.
Insulin Rapid må heller IKKE blandes med insuliner af animalsk oprindelse eller med insulinanaloger.
Insuman Rapid must also NOT be mixed with insulins of animal origin or with insulin analogues.
21. februar 1997 Dato for sidste genregistrering:
21 February 1997 Date of latest renewal:
21. februar 2007.
21 February 2007
Insuman Rapid 40 IE/ ml injektionsvæske, opløsning, i hætteglas
Insuman Rapid 40 IU/ ml solution for injection in a vial
Omstilling til Insuman Rapid
11 Transfer to Insuman Rapid
10 Dosisjustering (fx reduktion) kan være nødvendig umiddelbart efter præparatomstilling.
The need to adjust (e. g. reduce) the dose may become evident immediately after transfer.
Insuman Rapid indeholder 40 IE insulin pr. ml opløsning.
Insuman Rapid contains 40 IU of insulin per ml solution.
11 Inden omstilling til Insuman Rapid anbefales det at foretage en intradermal hudtest på de patienter, der er allergiske over for animalsk insulin, da disse patienter kan udvikle immunologiske krydsreaktioner.
In patients with an allergy to animal insulin intradermal skin testing is recommended prior to a transfer to Insuman Rapid, since they may experience immunological cross-reactions.
12 Interkurrente sygdomme
Intercurrent illness
Insuman Rapid kan anvendes under amning..
Insuman Rapid can be used during breastfeeding.
13 Patienter bør rådes til at tage forholdsregler for at undgå hypoglykæmi i forbindelse med bilkørsel.
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
14 Sygdomme i hud og subkutane væv
Skin and subcutaneous tissue disorders
15 Farmakodynamiske karakteristika
Pharmacodynamic characteristics
6. 3 Opbevaringstid
17 6.3 Shelf life
16 6. 5 Emballagetype og pakningsstørrelser
6.5 Nature and contents of container
10 ml opløsning i hætteglas (type1 farveløs glas) ombøjet hætte (aluminium), en prop (chlorbutylgummi (type 1)) og aftageligt låg (polypropylen).
10 ml solution in a vial (type 1 colourless glass) with a flanged cap (aluminium), a stopper (chlorobutyl rubber (type 1)) and a tear-off cap (polypropylene).
Insuman Rapid 100 IE/ ml injektionsvæske, opløsning, i cylinderampul
Insuman Rapid 100 IU/ ml solution for injection in a cartridge
Human insulin i Insuman Rapid fremstilles med rekombinant DNA- teknologi i af Escherichia coli.
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Omstilling til Insuman Rapid
20 Transfer to Insuman Rapid
18 Dosisjustering (fx reduktion) kan være nødvendig umiddelbart efter præparatomstilling.
The need to adjust (e. g. reduce) the dose may become evident immediately after transfer.
Insuman Rapid i cylinderampuller er udviklet til brug i penne af typen OptiPen.
Insuman Rapid in cartridges has been developed for use in the OptiPen series.
Patienter, der er overfølsomme over for Insuman Rapid, men hvor et bedre behandlingsalternativ ikke findes, må kun fortsætte behandlingen under særlig nøje kontrol og – om nødvendigt - i forbindelse med samtidig anti- allergisk behandling.
Patients hypersensitive to Insuman Rapid for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti- allergic treatment.
19 Inden omstilling til Insuman Rapid anbefales at foretage en intradermal hudtest på de patienter, der er allergiske over for animalsk insulin, da disse patienter kan udvikle immunologiske krydsreaktioner.
In patients with an allergy to animal insulin intradermal skin testing is recommended prior to a transfer to Insuman Rapid, since they may experience immunological cross-reactions.
20 Interkurrente sygdomme
Intercurrent illness
21 Patienter bør rådes til at tage forholdsregler for at undgå hypoglykæmi i forbindelse med bilkørsel.
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Øjensygdomme
24 Eyes disorders
22 En forbedret glykæmisk kontrol over lang tid mindsker risikoen for progression af diabetisk retinopati.
Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
23 Farmakodynamiske karakteristika
Pharmacodynamic characteristics
6. 3 Opbevaringstid
26 6.3 Shelf life
Insuma Rapid må ikke komme i direkte berøring med frostbokse eller fryseelementer.
Do not put Insuman Rapid next to the freezer compartment or a freezer pack.
Insulin- pen Cylinderampullerne skal anvendes i forbindelse med en insulin- pen såsom OptiPen og andre penne som passer til Insuman cylinderampuller, og som anbefalet i informationen fra fremstilleren af pennen.
Insulin pen The cartridges are to be used in conjunction with an insulin pen such as OptiPen and other pens suitable for Insuman cartridges and as recommended in the information provided by the device manufacturer.
Cylinderampuller Insuman Rapid skal opbevares ved stuetemperatur i 1 - 2 timer før det sættes ind i pennen.
Cartridges Before insertion into the pen, Insuman Rapid must be kept at room temperature for 1 to 2 hours.
Insuman Rapid 100 IE/ ml injektionsvæske, opløsning, i en fyldt pen
Insuman Rapid 100 IU/ ml solution for injection in a pre-filled pen.
Human insulin i Insuman Rapid fremstilles med rekombinant DNA- teknologi i Escherichia coli.
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Efter omstilling fra animalsk til human insulin vil dosisreduktion især være påkrævet hos patienter, der:
29 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Brugsanvisningen i indlægssedlen skal læses omhyggeligt før Optiset anvendes.
Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully
28 I tilfælde af utilstrækkelig glukosekontrol eller ved tendens til udvikling af hyper - eller hypoglykæmi skal følgende vurderes inden en eventuel dosisjustering: hvorvidt patienten har overholdt den ordinerede behandlingsforskrift, har fulgt forskrifterne for injektionssteder, anvendt korrekt injektionsteknik, samt hvorvidt øvrige relevante faktorer er opfyldt.
30 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
Anvendelse af pennen Brugsanvisningen i indlægssedlen skal læses omhyggeligt før Optiset anvendes.
Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully.
29 4. 5 Interaktion med andre lægemidler og andre former for interaktion
4.5 Interaction with other medicinal products and other forms of interaction
30 4. 8 Bivirkninger
32 4.8 Undesirable effects
32 5. 2 Farmakokinetiske egenskaber
5.2 Pharmacokinetic properties
5. 3 Prækliniske sikkerhedsdata
34 5.3 Preclinical safety data
33 6. 5 Emballagetype og pakningsstørrelser..
35 6.5 Nature and contents of container
Insuman Rapid OptiSet må kun anvendes, såfremt opløsningen er klar, farveløs, uden synlige partikler og har et vandlignende udseende.
Insuman Rapid must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of a water-like consistency.
Insuman Rapid må ikke blandes med andre insuliner eller insulinanaloger.
Insuman Rapid must not be mixed with any other insulin or with insulin analogues.
Brugsanvisningen i indlægssedlen skal læses omhyggeligt før Optiset anvendes.
Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
Beskyttelsessegl
Schematic diagram of the pen
34 • Hvis injektionen gives af en anden person, skal denne person udvise forsigtighed, for at undgå skader fra nålen og overførsel af infektioner. • Anvend aldrig OptiSet, hvis den er beskadiget, eller hvis De er usikker på om den virker korrekt. • Opbevar altid en ekstra OptiSet i tilfælde af at Deres OptiSet bliver væk eller går i stykker.
It must not be shared with anyone else. • If the injection is given by another person, special caution must be taken by this person to avoid accidental needle injury and transmission of infection. • Never use OptiSet if it is damaged or if you are not sure that it is working properly. • Always have a spare OptiSet in case your OptiSet is lost or damaged.
Opbevaringsbetingelser
36 Storage Instructions
35 Derefter trykkes dosisknappen helt i bund.
Then the injection button should be pressed all the way in.
Trin 4.
37 Step 4.
37 1.
39 1.
Omstilling til Insuman Rapid
40 Transfer to Insuman Rapid
38 Dosisjustering (fx reduktion) kan være nødvendig umiddelbart efter præparatomstilling.
The need to adjust (e. g. reduce) the dose may become evident immediately after transfer.